A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children’s Oncology Group Phase 1 Consortium Report

PURPOSE: To determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, and biologic effects of cixutumumab administered in combination with temsirolimus to children with refractory solid tumors. EXPERIMENTAL DESIGN: Cixutumumab and temsirolimus were administered in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Fouladi, Maryam, Perentesis, John P., Wagner, Lars M., Vinks, Alexander A., Reid, Joel M., Ahern, Charlotte, Thomas, George, Mercer, Carol A., Krueger, Darcy A., Houghton, Peter J., Doyle, L. Austin, Chen, Helen, Weigel, Brenda, Blaney, Susan M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4454739/
https://ncbi.nlm.nih.gov/pubmed/25467181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0595
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak